Ninety-four percent of patients and care partners in an acceptability study rated the Leqembi Iqlik autoinjector easy to use at home, and that single statistic captures exactly why this FDA approval matters more to Eisai and BioArctic commercially than it does clinically. The FDA cleared subcutaneous lecanemab as a starting dose on July 13, 2026, meaning patients can now begin and maintain treatment entirely via once-weekly self-injection, never setting foot in an infusion suite. That eliminates one of the most persistent friction points blocking real-world uptake of anti-amyloid therapy since lecanemab first earned traditional IV approval in July 2023.
The clinical data package rests on Clarity AD long-term extension sub-studies showing that weekly subcutaneous dosing achieves exposure equivalent to IV, with a safety profile the FDA found comparable. ARIA-E rates track alongside IV administration, and there was no increase in isolated ARIA-H relative to placebo. Those findings matter because ARIA risk has been the central clinical hesitation across this entire drug class, and any suggestion that the route switch worsened it would have complicated the commercial story badly. Instead, Eisai gets to argue that SC initiation is a genuine equivalence story, not a compromise. The approved regimen is 500 mg weekly for initiation (two 250 mg injections, each delivered in roughly 15 seconds), then a step down to 360 mg weekly for maintenance once 18 months of treatment are complete.
The competitive dimension is real. Kisunla (donanemab), Eli Lilly’s IV anti-amyloid antibody approved in July 2024, has no subcutaneous formulation currently on the market, which means Leqembi Iqlik now occupies territory Lilly cannot match on administration convenience. Infusion-center capacity has been a documented bottleneck for both products, and the ability to route patients to home dosing from day one reduces dependence on that infrastructure meaningfully. Patients can also switch between IV and SC as their circumstances change, which gives prescribers flexibility that a single-modality competitor cannot offer.
With a US launch planned for late August 2026, the number worth tracking in the next two quarters is the proportion of new lecanemab starts choosing SC over IV. If that share climbs above 50 percent quickly, it signals that the administration barrier was suppressing demand more than price or ARIA monitoring concerns, and the revenue trajectory for the entire franchise will need to be revised upward.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
